Delving into the Latest Updates on Umbilical Cord Blood Derived MAK Immune Cells(Zhongnan hospital of wuhan university) with Synapse

Overview

Basic Info

Drug Type

Immune cell therapy

Synonyms-

Target

MAK

Action

modulators

Mechanism

MAK modulators(male germ cell associated kinase modulators)

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Zhongnan hospital of wuhan university

Active Organization-

Inactive Organization-

License Organization-

Drug Highest Phase-

First Approval Date-

Regulation-

To evaluate the safety of MAK immune cells derived from umbilical cord blood combined with second-line treatments for hepatobiliary and pancreatic malignancies.And to investigate the initial efficacy of MAK immune cells derived from umbilical cord blood combined with second-line treatments for hepatobiliary and pancreatic malignancies.

Start Date07 Feb 2022

Sponsor / Collaborator

Zhongnan hospital of wuhan university

100 Clinical Results associated with Umbilical Cord Blood Derived MAK Immune Cells(Zhongnan hospital of wuhan university)

Login to view more data

100 Translational Medicine associated with Umbilical Cord Blood Derived MAK Immune Cells(Zhongnan hospital of wuhan university)

Login to view more data

100 Patents (Medical) associated with Umbilical Cord Blood Derived MAK Immune Cells(Zhongnan hospital of wuhan university)

Login to view more data

100 Deals associated with Umbilical Cord Blood Derived MAK Immune Cells(Zhongnan hospital of wuhan university)

Login to view more data